Form 4: Acadia Pharmaceuticals Executive Acquires Shares and Stock Options
SEC Form 4
Jennifer J. Rhodes, EVP, Chief Legal Officer, and Secretary of Acadia Pharmaceuticals, reports acquiring shares through the Employee Stock Purchase Plan and stock options and restricted stock units as part of her compensation.
Summary
- Jennifer J. Rhodes, an executive at Acadia Pharmaceuticals, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
- On March 24, 2025, Rhodes acquired 1,020 shares of common stock through the Employee Stock Purchase Plan.
- She also acquired options to purchase 102,289 shares of common stock at an exercise price of $17.23, vesting in installments starting March 24, 2026.
- Additionally, Rhodes acquired 30,062 restricted stock units (RSUs), each representing a contingent right to receive one share of Acadia Pharmaceuticals common stock, vesting in equal annual installments beginning March 24, 2026.
- Following these transactions, Rhodes directly owns 1,020 shares of common stock, options for 102,289 shares, and 30,062 RSUs.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. There are no explicit positive or negative implications for the company's performance.
Positives
- The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules for the stock options and RSUs suggest a multi-year commitment from the executive.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. This filing is typical for executives receiving stock-based compensation.
Comparison to Industry Standards
- Stock option and RSU grants are a common component of executive compensation packages in the pharmaceutical industry.
- Vesting schedules, such as the one described in the document, are standard practice to incentivize long-term performance and retention.
- The specific amounts and terms of the grants would need to be compared to peer companies to assess their competitiveness.
Stakeholder Impact
- The transactions reported in the Form 4 have a minimal direct impact on stakeholders.
- Shareholders may view the executive's increased stake in the company as a positive sign.
Key Dates
| Date | Description |
|---|---|
| November 15, 2024 | Shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan. |
| March 24, 2025 | Date of the reported transaction. |
| March 24, 2026 | 25% of the shares subject to the Stock Option will vest and become exercisable. The restricted stock units vest in four equal annual installments beginning on this date. |
| March 23, 2035 | Expiration date of the stock options. |
| March 26, 2025 | Date of signature. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Employee Stock Purchase Plan, Acadia Pharmaceuticals, Securities, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.